Efficacy of AMALS in Treating Language Impairment in Children
NCT ID: NCT00840060
Last Updated: 2012-05-15
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
40 participants
INTERVENTIONAL
2009-01-31
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Questions driving this work are:
1. Will children participating in the AMALS treatment exhibit greater semantic, morphological, and syntactic complexity on multiple outcome measures at the completion of the intervention compared to a Discrete Trial Approach (DTA) group?
2. Will these gains be maintained at one-month follow up?
3. What is the impact of dialect on dependent variables, specifically morphosyntactic abilities?
To answer these questions a randomized clinical trial will be conducted comparing AMALS, an integrated approach to treatment, with DTA, an additive approach to therapy. In this study rather than restrict the ethnic and cultural backgrounds of this population, children's use of dialect will be uniquely identified and examined.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Determining Optimal Treatment Intensity for Children With Language Impairment
NCT04501536
Testing a Novel Speech Intervention in Minimally Verbal Children With Autism Spectrum Disorder (ASD)
NCT03015272
The Relationship Between Child Language Proficiency and Language of Treatment on the Outcomes of Bilingual Children with Developmental Language Disorder
NCT06085300
Efficiency of Speech and Language Intervention on Achievement of Children With Developmental Language Disorder
NCT04926311
Written Language Intervention for Adults With Intellectual and Developmental Disabilities
NCT05851937
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AMALS
Addressing multiple aspects of language simultaneously
AMALS
Addressing multiple aspects of language simultaneously
DTA
Discrete Trial Approach
DTA
Discrete Trial Approach
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AMALS
Addressing multiple aspects of language simultaneously
DTA
Discrete Trial Approach
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Demonstrate sufficient phonological ability to use grammatical morphemes as determined by use of word-final /s, z, t, d/ on sound- in-word subtest from the Goldman-Fristoe Test of Articulation-2 (GFTA; Goldman \& Fristoe, 2000)
3. Nonverbal IQ above 70 as scored on the Columbia Mental Maturity Scale (CMMS; Burgemeister, Blum, \& Lorge, 1972);
4. Below 1SD on the Diagnostic Evaluation of Language Variation: Norm-referenced Test (DELV; Seymour, Roeper \& de Villiers, 2005);
5. Below 1.39SD on the Structured Photographic Expressive Language Test-Preschool (SPELT-P; Werner \& Kresheck, 1983);
6. Documentation from teachers and/or parents of impressions of language status in comparison with peers;
7. More than one standard deviation below the mean on both levels 3 and 4 of the Preschool Language Assessment Instrument (PLAI; Blank, Rose, \& Berlin, 1978).
Exclusion Criteria
2. No oral-motor impairment
3. No hearing impairment
4. No co-morbid psychiatric or neurological impairments
4 Years
6 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Lamar University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Monica L. Harn
Associate Professor, Speech and Hearing Services
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Monica L Bellon-Harn, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Lamar University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
West Orange Cove Consolidated Independent School District
Orange, Texas, United States
Little-Cypress Mauriceville Consolidated School District
Orange, Texas, United States
Port Arthur Independent School District
Port Arthur, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIDCD RDC009027A-01A2
Identifier Type: -
Identifier Source: secondary_id
RDC009027A-01A2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.